As you've heard, and as we noted in our testimony, about 75% of our activity in this country is in clinical trials. That mirrors about 75% to 80% of global activity of the pharmaceutical industry funding clinical trials. It's in our interest to do so, to bring new medicines to patients.
I'd like to point out, though, that there is a lot of independent research, and Health Canada must approve every clinical trial that happens in this country. There is also posting of those trials in the context of ClinicalTrials.gov, and the new initiative that Minister Aglukkaq started and that Minister Ambrose has picked up.
There's a lot of transparency and disclosure of those results. They are conducted—if we have more time, I can walk through the steps—with a high degree of regulator rigour and independence in evaluating the results of the trials. Again, as I pointed out, most clinical trials fail for the reasons of unacceptable safety profiles.